Quality HTA in ValleyML 2021 - Quality HTA is honoured to present AI in HTA. Pooyeh Graili, the principal consultant at Quality HTA, will talk about "Artificial Intelligence in Health Technology Assessment" on October 12, 2021, at 13:00 EDT. The VallyMl virtual event will be held from October 12 - 14 on various topics, including AI in healthcare. To register: here [...]
Quality HTA & HTAi Webinar - Quality HTA is honoured to contribute to holding a webinar "Artificial Intelligence in Outcomes Research" presenting by Pooyeh Graili, the principal consultant at Quality HTA, in the third Quarterly Meeting of RWE & AI IG (Real-world Evidence & Artificial Intelligence Interest Group) at HTAi on Thursday, September 16 at [...]
Over 100 Viewers in Four Months - Quality HTA is honored with its last article, "Artificial intelligence in outcomes research: a systematic scoping review" published four months ago by Expert Rev Pharmacoecon Outcomes Res Journal @tandfonline, which has been viewed over 100 times! Thanks very much to the viewers for their interest, the co-authors for [...]
CADTH & Advisory Panel for a Pan-Canadian Prescription Drug List - CADTH was chosen to establish the Advisory Panel to develop a framework for a pan-Canadian prescription drug list. CADTH will provide this service to Health Canada due to its relationship with federal, provincial, and territorial jurisdictions and other healthcare stakeholders on top of its [...]
Only One Submission at the EU level! The joint clinical assessment of new health technologies is a valuable step to accelerate patients' access to new health technologies, manufacturers' access to the market and increase the efficiency of national HTA bodies' assessments to make informed pricing and reimbursement decisions. The value of this joint work on [...]
Artificial Intelligence in the Regulatory Processes - Artificial intelligence can accelerate the drug development process and reduce its cost by virtual screening new molecules and optimizing patient recruitment in trials. Artificial intelligence can accelerate the drug development process and reduce its cost by virtual screening new molecules and optimizing patient recruitment in trials. According to [...]
The Challenges of Regulatory and HTA Bodies in RWE - An interesting qualitative article by Silvers H. et al. about the perspectives on challenges, values & alignment of regulatory and HTA bodies. Great findings which could be an excellent opportunity for quantitative research if saturation was reached in all interviewed groups. Regulatory and HTA bodies need [...]
Artificial Intelligence in Outcomes Research - Quality HTA is pleased to announce its recent paper “Artificial Intelligence in Outcomes Research: A Systematic Scoping Review” published online by the Expert Review of Pharmacoeconomics & Outcomes Research journal. This study aims to systematically capture the scope of artificial intelligence methods used in outcomes research studies to enhance [...]
The Impact of COVID-19 on HTA - Regulation bodies and HTA agencies might need to use RWE more than ever and/or re-evaluate listed technologies using the RWE to cease reimbursement of low-value health technologies due to COVID-19. A great article about the Impact of the Pandemic on HTA by Paula K. Lorgelly and Amanda Adler: [...]
Happy 2021! Wishing you and your family a year full of health and happiness!